# A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

> **NCT03783403** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 206 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** CC-95251
- **DRUG:** Rituximab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT03783403
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-01
- **Primary completion:** 2024-08-05
- **Final completion:** 2024-08-05
- **Target enrollment:** 206 (ACTUAL)
- **Why stopped:** Business objectives have changed.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03783403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03783403, "A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03783403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*